Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAIA-102 in Refractory/Relapse Neuroblastomas and Pediatric Solid Tumors
NCT05608148Phase 1Recruiting
- Sponsor
- Kyushu University
- Start
- Oct 2022
- Primary completion
- Aug 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of GAIA-102 in neuroblastoma and Pediatric solid tumor (PST) (4 arms), sponsored by Kyushu University. Primary endpoints: Dose Limiting Toxicity at 56 days and Adverse Events at 2 years. Started Oct 2022; status: recruiting.
02
Drugs
GAIA-102
03
Conditions
neuroblastomaPediatric solid tumor (PST)
Beyond the preview
Go deeper on NCT05608148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05608148.